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Current ACC guidelines have class 2A recommendations that pretreatment with class 1c or class 3 anti-arrhythmic drugs can enhance the acute 
success rate of electrical cardioversion of atrial fibrillation. Efficacy of pretreatment with Dronedarone, a new class 3 anti-arrhythmic drug is 
currently unknown.
Methods: A retrospective chart review of all patients with atrial fibrillation that underwent electrical cardioversion during the years 2007 to 2010. 
Successful electrical cardioversion was defined as acute conversion to sinus rhythm and maintenance of the rhythm for at least 2 hours. Patients 
were divided into two groups. One group received pre-treatment with class 1c or class 3 anti-arrhythmic drugs before electrical cardioversion and 
other group did not. Pre-treatment was defined as initiation of these drugs any time before the procedure.
Results: Out of 255 patients of atrial fibrillation that underwent electrical cardioversion, 41 failed the procedure resulting in overall 84% success 
rate. The group receiving pretreatment had 101 patients and 12 failed cardioversions (88% success rate). The group which did not receive the 
pretreatment had 154 patients and 29 failed cardioversions (81% success rate). This difference was not statistically significant. The success rate of 
individual drugs used for pretreatment showed that Dronedarone had a lower success rate of 71% (11 successful and 5 failed) when compared with 
Amiodarone 96% (24 successful and 1 failed) and Propafenone 100% (19 successful and 0 failed) and this difference was statistically significant. 
A co-variable analysis did not show any difference between the patients in Dronedarone or Amiodarone/Propafenone sub-groups in terms of 
duration of atrial fibrillation, size of left atrium and Left ventricular ejection fraction. The success rate of Dronedarone was also lower than Sotalol 
(26 successful and 4 failed), Dofetilide (2 successful and 0 failed) and Flecanide (5 successful and 0 failed) but this difference was not statistically 
significant.
Conclusion: Pretreatment with Dronedarone was inferior to Amiodarone and Propafenone in improving the acute success rate of electrical 
cardioversion of atrial fibrillation.
